Federal Register / Vol. 79, No. 247 / Wednesday, December 24, 2014 / Notices 77477 

ENVIRONMENTAL PROTECTION 

AGENCY 

[EPA–HQ–OPP–2014–0737; FRL–9920–77] 

Benefits of Neonicotinoid Seed 

Treatment to Soybean Production; 

Reopening of Comment Period 

AGENCY: Environmental Protection 

Agency (EPA). 

ACTION: Notice; reopening of comment 

period. 

SUMMARY: EPA issued a notice in the 

Federal Register of October 22, 2014, 

concerning the assessment the Agency 

conducted as part of its ongoing reevaluation of clothianidin, 

imidacloprid, and thiamethoxam under 

the registration review program. This 

assessment examines the use of 

clothianidin, imidacloprid, and 

thiamethoxam seed treatments in terms 

of the extent of use and the pests 

targeted in order to characterize overall 

benefits to soybean production 

nationwide. In response to requests, the 

EPA is reopening the public comment 

period of EPA’s analysis of Benefits of 

Neonicotinoid Seed Treatments to 

Soybean Production. This document 

reopens the comment period for 30 days 

to January 23, 2015. 

DATES: Comments, identified by docket 

identification (ID) number EPA–HQ– 

OPP–2014–0737, must be received on or 

before January 23, 2015. 

ADDRESSES: Follow the detailed 

instructions provided under ADDRESSES

in the Federal Register document of 

October 22, 2014 (79 FR 63118) (FRL– 

9917–55). 

FOR FURTHER INFORMATION CONTACT: For 

pesticide specific information, contact: 

Carissa Cyran, Pesticide Re-Evaluation 

Division (7508P), Office of Pesticide 

Programs, Environmental Protection 

Agency, 1200 Pennsylvania Ave. NW., 

Washington, DC 20460–0001; telephone 

number: (703) 347–8781; email address: 

cyran.carissa@epa.gov. 

For general information on the 

registration review program, contact: 

Richard Dumas, Pesticide Re-Evaluation 

Division (7508P), Office of Pesticide 

Programs, Environmental Protection 

Agency, 1200 Pennsylvania Ave. NW., 

Washington, DC 20460–0001; telephone 

number: (703) 308–8015; email address: 

dumas.richard@epa.gov. 

SUPPLEMENTARY INFORMATION: This 

document reopens the public comment 

period established in the Federal 

Register document of October, 22, 2014. 

In that document, the Agency 

announced that it had conducted an 

assessment as part of its ongoing reevaluation of clothianidin, 

imidacloprid, and thiamethoxam under 

the registration review program. This 

assessment examines the use of 

clothianidin, imidacloprid, and 

thiamethoxam seed treatments in terms 

of the extent of use and the pests 

targeted in order to characterize overall 

benefits to soybean production 

nationwide. EPA is hereby reopening 

the comment period for 30 days, to 

January 24, 2015. 

To submit comments, or access the 

docket, please follow the detailed 

instructions provided under ADDRESSES

in the Federal Register document of 

October 22, 2014. If you have questions, 

consult the person listed under FOR

FURTHER INFORMATION CONTACT. 

Authority: 7 U.S.C. 136 et seq. 

Dated: December 17, 2014. 

Richard P. Keigwin, Jr., 

Director, Pesticide Re-Evaluation Division, 

Office of Pesticide Programs. 

[FR Doc. 2014–30089 Filed 12–23–14; 8:45 am] 

BILLING CODE 6560–50–P 

ENVIRONMENTAL PROTECTION 

AGENCY 

[EPA–HQ–OPP–2014–0817; FRL–9919–30] 

Registration Review Final and Interim 

Decisions; Notice of Availability 

AGENCY: Environmental Protection 

Agency (EPA). 

ACTION: Notice. 

SUMMARY: This notice announces the 

availability of EPA’s final/interim 

registration review decisions. 

Registration review is EPA’s periodic 

review of pesticide registrations to 

ensure that each pesticide continues to 

satisfy the statutory standard for 

registration, that is, that the pesticide 

can perform its intended function 

without causing unreasonable adverse 

effects on human health or the 

environment. Through this program, 

EPA is ensuring that each pesticide’s 

registration is based on current 

scientific and other knowledge, 

including its effects on human health 

and the environment. 

FOR FURTHER INFORMATION CONTACT: For 

pesticide specific information, contact: 

The Chemical Review Manager for the 

pesticide of interest identified in the 

table in Unit II.A. 

For general information on the 

registration review program, contact: 

Richard Dumas, Pesticide Re-Evaluation 

Division (7508P), Office of Pesticide 

Programs, Environmental Protection 

Agency, 1200 Pennsylvania Ave. NW., 

Washington, DC 20460–0001; telephone 

number: (703) 308–8015; email address: 

dumas.richard@epa.gov. 

SUPPLEMENTARY INFORMATION: 

I. General Information 

A. Does this action apply to me? 

This action is directed to the public 

in general, and may be of interest to a 

wide range of stakeholders including 

environmental, human health, farm 

worker, and agricultural advocates; the 

chemical industry; pesticide users; and 

members of the public interested in the 

sale, distribution, or use of pesticides. 

Since others also may be interested, the 

Agency has not attempted to describe all 

the specific entities that may be affected 

by this action. If you have any questions 

regarding the applicability of this action 

to a particular entity, consult the 

pesticide specific contact person listed 

under FOR FURTHER INFORMATION

CONTACT. 

B. How can I get copies of this document 

and other related information? 

The docket for this action, identified 

by docket identification (ID) number 

EPA–HQ–OPP–2014–0817, is available 

at http://www.regulations.gov or at the 

Office of Pesticide Programs Regulatory 

Public Docket (OPP Docket) in the 

Environmental Protection Agency 

Docket Center (EPA/DC), West William 

Jefferson Clinton Bldg., Rm. 3334, 1301 

Constitution Ave. NW., Washington, DC 

20460–0001. The Public Reading Room 

is open from 8:30 a.m. to 4:30 p.m., 

Monday through Friday, excluding legal 

holidays. The telephone number for the 

Public Reading Room is (202) 566–1744, 

and the telephone number for the OPP 

Docket is (703) 305–5805. Please review 

the visitor instructions and additional 

information about the docket available 

at http://www.epa.gov/dockets. 

II. What action is the Agency taking? 

Pursuant to 40 CFR 155.58(c), this 

notice announces the availability of 

EPA’s final/interim registration review 

decision for 4-CPA & salts (Case 2115), 

Acetaminophen (Case 7610), Allethrins 

(Case 0473), Clofentezine (Case 7602), 

Cyromazine (Case 7439), Fosthiazate 

(Case 7604), Hexythiazox (Case 7404), 

Lactofen (Case 7210), Macleaya Extract 

(Case 7024), Trinexapac-ethyl (Case 

7228), and Quizalofop (Case 7215). 

Pursuant to 40 CFR 155.57, a 

registration review decision is the 

Agency’s determination whether a 

pesticide meets, or does not meet, the 

standard for registration in FIFRA. EPA 

has considered for 4-CPA & salts (Case 

2115), Acetaminophen (Case 7610), 

Allethrins (Case 0473), Clofentezine 

(Case 7602), Cyromazine (Case 7439), 

mstockstill on DSK4VPTVN1PROD with NOTICES

77478 Federal Register / Vol. 79, No. 247 / Wednesday, December 24, 2014 / Notices 

Fosthiazate (Case 7604), Hexythiazox 

(Case 7404), Lactofen (Case 7210), 

Macleaya Extract (Case 7024), 

Trinexapac-ethyl (Case 7228), and 

Quizalofop (Case 7215) in light of the 

FIFRA standard for registration. For 4- 

CPA & salts (Case 2115), Allethrins 

(Case 0473). Clofentezine (Case 7602), 

Cyromazine (Case 7439), Fosthiazate 

(Case 7604), Hexythiazox (Case 7404), 

Lactofen (Case 7210), Macleaya Extract 

(Case 7024), Trinexapac-ethyl (Case 

7228), and Quizalofop (Case 7215), the 

Final/Interim Decision documents in 

the docket describe the Agency’s 

rationale for issuing a registration 

review final/interim decision for each of 

these pesticides. 

In addition to the final/interim 

registration review decision document, 

the registration review docket for 4-CPA 

& salts, Acetaminophen, Clofentezine, 

Cyromazine, Fosthiazate, Hexythiazox, 

Lactofen, Macleaya Extract, Trinexapacethyl, and Quizalofop also includes 

other relevant documents related to the 

registration review of this case. The 

proposed final/interim registration 

review decisions were posted to the 

docket and the public was invited to 

submit any comments or new 

information. 

REGISTRATION REVIEW FINAL AND INTERIM DECISIONS

Registration review case name and 

No. Pesticide docket ID No. Chemical review manager, telephone number, email address 

4-CPA (Case 2115) ......................... EPA–HQ–OPP–2014–0544 Miguel Zavala, 703–347–0504, zavala.miguel@epa.gov. 

Acetaminophen (Case 7610) ........... EPA–HQ–OPP–2012–0145 Bonnie Adler, 703–308–8523, adler.bonnie@epa.gov. 

Allethrins (Case 0473) ..................... EPA–HQ–OPP–2010–0022 Marianne Mannix, 703–347–0275, mannix.marianne@epa.gov. 

Clofentezine (Case 7602) ................ EPA–HQ–OPP–2006–0240 Wilhelmena Livingston, 703–308–8025, livingston.wilhelmena@epa.gov. 

Cyromazine (Case 7439) ................. EPA HQ–OPP–2006–0108 James Parker, 703–306–0469, parker.james@epa.gov. 

Fosthiazate (Case 7604) ................. EPA–HQ–OPP–2009–0267 James Parker, 703–306–0469, parker.james@epa.gov. 

Hexythiazox (Case 7404) ................ EPA–HQ–OPP–2006–0114 Miguel Zavala, 703–347–0504, zavala.miguel@epa.gov. 

Lactofen (Case 7210) ...................... EPA–HQ–OPP–2005–0287 Kelly Ballard, 703–305–8126, ballard.kelly@epa.gov. 

Macleaya Extract (Case 7024) ........ EPA–HQ–OPP–2011–0172 Susan Bartow, 703–603–0065, bartow.susan@epa.gov. 

Trinexapac-ethyl (Case 7228) ......... EPA–HQ–OPP–2008–0657 Brittany Pruitt, 703–347–0289, pruitt.brittany@epa.gov. 

Quizalofop (Case 7215) ................... EPA–HQ–OPP–2007–1089 Khue Nguyen, 703–347–0248, nguyen.khue@epa.gov. 

EPA addresses the comments or 

information received during the 60-day 

comment period in the discussion for 

each pesticide listed in this document. 

During the 60-day comment period, no 

public comments were received for 

fosthiazate or 4–CPA, while cyromazine, 

hexythiazox and macleaya extract each 

received a single comment from the 

Center for Biological Diversity which 

did not affect the Agency’s interim 

decisions. 

4–CPA (Interim Decision). The 

registration review docket for 4–CPA 

(EPA–HQ–OPP–2014–0544) opened in a 

notice published in the Federal Register 

of September 24, 2014 (79 FR 57084) 

(FRL–9916–39). 4–CPA is a plant 

growth regulator registered for use 

exclusively as a soaking agent for mung 

bean sprouts in greenhouse operations 

to prevent root formation. EPA 

conducted a qualitative assessment for 

both human health and environmental 

fate and ecological risks. No risks of 

concern were identified and the Agency 

has made a ‘‘no effect’’ determination 

for federally listed endangered and 

threatened (listed) species as well as a 

‘‘no habitat modification’’ determination 

for all designated critical habitat. In this 

Interim Registration Review Decision, 

EPA is not making human health or 

environmental safety findings 

associated with the Endocrine Disrupter 

Screening Program (EDSP) for 4–CPA. 

Before completing this Registration 

Review, the Agency will make an EDSP 

FFDCA section 408(p) determination. 

Acetaminophen (Final Registration 

Review Decision). Acetaminophen (also 

known as the active ingredient in 

Tylenol) is registered for use as a 

vertebrate pesticide to control the 

invasive brown tree snake in Guam. The 

snakes ingest baited mice, which are 

lethal to the snake. There are no 

registered food/feed uses for 

acetaminophen, and no tolerances have 

been established. The Agency 

conducted an ecological risk and 

endangered species assessment for 

acetaminophen, and concluded, based 

on the limited opportunities for nontarget species to be exposed, that there 

are no risks of concern for native, nontarget organisms associated with the 

pesticidal use of acetaminophen. 

Furthermore, the Agency made a ‘‘no 

effects’’ determination for all federally 

listed species and a ‘‘no adverse 

modification of critical habitat’’ 

determination. A human health risk 

assessment was not conducted due to 

acetaminophen’s well-studied 

pharmaceutical use and the extremely 

limited opportunities for human 

exposure from its pesticidal use on 

Guam. In addition, EPA recently has 

determined that acetaminophen is 

exempt from requirements of the 

endocrine disruptor screening program. 

The Agency proposed in June of 2014 

that risk mitigation measures were not 

needed, and several comments were 

received in support of that decision. 

This notice finalizes the Agency’s 

registration review decision on 

acetaminophen. 

Allethrins (Interim Decision). The 

registration review docket for the 

allethrin stereoisomers (EPA–HQ–OPP– 

20 1 0–0022) opened in a notice 

published in the Federal Register of 

March 30, 2010 (75 FR 16117) (FRL– 

8814–4). The allethrin stereoisomers 

include bioallethrin, esbiol, esbiothrin, 

and pynamin forte. All allethrins 

registrations, with the exception of three 

products (71910–2, 71910–3, and 

71910–4) were cancelled effective 

December 2016. The only remaining 

registered uses of allethrins are 

impregnated mats for control of flying 

pests such as mosquitoes. 

There are no occupational, food or 

feed uses of allethrins. EPA conducted 

draft assessments for human health risks 

and ecological risks for the purposes of 

registration review. No risks of concern 

were identified in the human health risk 

assessment. The ecological risk 

assessment indicated that there was no 

reasonable expectation for the 

remaining registered uses of allethrins 

stereoisomers to cause direct or indirect 

adverse effects to threatened and 

endangered species. A ‘‘no effect’’ 

determination was made for all federally 

listed species as well as a ‘‘no habitat 

modification’’ determination made for 

all designated critical habitat. The 

allethrins stereoisomers have not been 

evaluated under the EDSP. Therefore, 

the Agency’s final registration review 

decision is dependent upon the result of 

the evaluation of potential endocrine 

disrupter risk. Pending the outcome of 

this action, EPA is issuing an interim 

mstockstill on DSK4VPTVN1PROD with NOTICES

Federal Register / Vol. 79, No. 247 / Wednesday, December 24, 2014 / Notices 77479 

registration review decision for 

allethrins. 

Clofentezine (Interim Decision). The 

registration review docket for 

clofentezine (EPA–HQ–OPP–2006– 

0240) opened in a notice published in 

the Federal Register of March 2007 (72 

FR 14548) (FRL–8118–3). Clofentezine 

is an acaricide registered for use to 

control mites. It is a liquid formulation 

for use on almonds, apples, apricots, 

cherries, Christmas trees (except 

California) and Christmas tree 

plantations, grapes (except New York), 

nectarines, ornamentals (greenhouse 

and outdoor), peaches, pears, 

persimmons, and walnuts. There are 

currently no registered residential uses 

of clofentezine. The Agency conducted 

a human health risk assessment and did 

not identify any risks of concern. The 

ecological risk assessment determined 

that all outdoor uses of clofentezine can 

potentially lead to direct adverse effects 

to listed and non-listed birds. As birds 

serve as surrogates to reptiles and 

terrestrial-phase amphibians, risk to 

these taxa is also a possibility. The use 

of clofentezine is not expected to pose 

a risk to foraging (adult) bees; however, 

there is a potential for risk to non-listed 

and listed terrestrial arthropods because 

of adverse effects to reproduction and 

development. To address this 

uncertainty, the Agency is requiring a 

chronic honey bee larval toxicity test to 

determine any reproductive effects to 

pollinators. This interim decision does 

not cover the EDSP component of the 

clofentezine registration review case. 

Additionally, the ecological risk 

assessment for clofentezine did not 

come to a conclusion of ‘‘no effect’’ to 

some listed species. Therefore, 

consultation with the Fish and Wildlife 

Service on the potential risk of 

clofentezine to some listed species will 

be necessary. The Agency’s final 

registration review decision for 

clofentezine will occur after an EDSP 

FFDCA Section 408(p) determination, 

and after the result of the Section 7 

Endangered Species consultation with 

the U.S. Fish and Wildlife Service as 

well as an assessment on the non-target 

exposure to bees. 

Cyromazine (Interim Decision). The 

registration review docket for 

cyromazine (EPA–HQ–OPP–2006–0108) 

opened in a notice published in the 

Federal Register of March 28, 2007 (72 

FR 14548) (FRL–8118–3). Cyromazine is 

a triazine which acts as an insect growth 

regulator. Cyromazine is registered for 

use on several agricultural crops such as 

beans, peppers, and tomatoes; it is 

registered for use on indoor 

ornamentals, and to control flies in 

manure. There are no residential uses 

for cyromazine. EPA conducted a 

human health occupational risk 

assessment and did not identify any 

risks of concern. The ecological risk 

assessment identified potential risks to 

several taxa including birds, mammals, 

and bees. To mitigate potential 

ecological risks, the Agency will 

increase the application interval for 

cyromazine use on potatoes; add label 

language for the onion seed treatment 

use; add precautionary label language to 

reduce risk to bees; and, increase the 

minimum droplet size for aerial 

applications. These changes will reduce 

estimated risks. The Agency did not 

reach a conclusion of ‘‘no effect’’ to any 

listed species. Therefore, consultation 

with the Fish and Wildlife Service 

(FWS) on the potential risk of 

cyromazine to listed species will be 

necessary. Cyromazine has not been 

evaluated under EDSP. Therefore, the 

Agency’s final registration review 

decision is dependent on the results of 

consultation under section 7 of the 

Endangered Species Act (ESA) (16 

U.S.C. 1536) with the FWS and the 

evaluation of potential endocrine 

disruptor risk. Pending the outcome of 

these actions, EPA is issuing an interim 

registration review decision for 

cyromazine. 

Fosthiazate (Interim Decision). The 

registration review docket for 

fosthiazate (EPA–HQ–OPP–2009–0267) 

opened in a notice published in the 

Federal Register of June 24, 2009 (74 FR 

30077) (FRL–8422–4). Fosthiazate is an 

organophosphate nematicide for use 

only on tomatoes, via drip irrigation 

under plastic. There are no residential 

uses for fosthiazate. EPA conducted a 

human health dietary and occupational 

risk assessment for fosthiazate and did 

not identify any risks of concern. The 

ecological risk assessment identified 

potential risks to several taxa including 

birds, mammals, and soil-bound 

terrestrial invertebrates. To mitigate 

potential ecological risks, the agency 

will modify the application directions 

for fosthiazate to increase the volume of 

water required for application. The 

Agency did not not reach a conclusion 

of ‘‘no effect’’ to listed species. 

Therefore, consultation with FWS on 

the potential risk of fosthiazate to listed 

species will be necessary. Fosthiazate 

has not been evaluated under EDSP. 

Therefore, the Agency’s final 

registration review decision is 

dependent on the results of consultation 

under ESA section 7 with FWS and the 

evaluation of potential endocrine 

disruptor risk. The EPA is issuing an 

interim registration review decision for 

fosthiazate. 

Hexythiazox (Interim Decision). The 

registration review docket for 

hexythiazox (EPA–HQ–OPP–2006– 

0114) opened in a notice published in 

the Federal Register of February 2, 2007 

(72 FR 5050) (FRL–8113–1). 

Hexythiazox is an acaricide that acts 

primarily as a mite growth inhibitor/

ovicide and is used to control mites. It 

is registered for use on a variety of 

agricultural crops, turf, and various 

residential plants. The Agency 

conducted a human health risk 

assessment and did not identify any 

risks of concern. The ecological risk 

assessment identified potential risks of 

concern to non-target terrestrial 

invertebrates (e.g., bees) and chronic 

risk to fish due to lack of data. The 

Agency is therefore requiring an honey 

bee larval toxicity study to determine 

any reproductive effects to pollinators. 

While chronic risk to fish and non-target 

invertebrates is uncertain due to data 

gaps, the potential risks are expected to 

be low as hexythiazox is applied only 

once per year at a low rate and is not 

highly persistent in the environment. 

The risk assessment for hexythiazox did 

not come to a conclusion of ‘‘no effect’’ 

to listed species. Therefore, consultation 

with FWS and the National Marine 

Fisheries Service (NMFS) (the Services) 

on the potential risk of hexythiazox to 

listed species will be necessary. 

Hexythiazox has not been evaluated 

under the EDSP. Therefore, the 

Agency’s final registration review 

decision is dependent on the result of 

consultation under ESA section 7 with 

the Services,the evaluation of potential 

endocrine disruptor risk, as well as an 

assessment on the non-target exposure 

to bees. Pending the outcome of these 

actions, EPA is planning to issue a 

registration review decision for 

hexythiazox. 

Lactofen (lnterim Decision). The 

registration review docket for lactofen 

(EPA–HQ–OPP–2005–0287) opened in a 

notice published in the Federal Register 

of February 2, 2007 (72 FR 5050) (FRL– 

8113–1). Lactofen is a light dependent 

peroxidizing herbicide (LDPH) with 

uses on conifer seedlings, cotton, kenaf. 

peanuts, soybean, and with Statespecific uses on fruiting vegetables, 

okra, and snap beans. There are no 

residential uses for lactofen. EPA 

conducted a human health occupational 

risk assessment and did not identify any 

risks of concern. The ecological risk 

assessment identified potential risks to 

several different taxa. However, due to 

the number of conservative assumptions 

included in the assessment, and 

additional use and usage information to 

help characterize potential risks, the 

mstockstill on DSK4VPTVN1PROD with NOTICES

77480 Federal Register / Vol. 79, No. 247 / Wednesday, December 24, 2014 / Notices 

Agency is not proposing mitigation 

changes at this time. The risk 

assessment for lactofen did not come to 

a conclusion of ‘‘no effect’’ to listed 

species. Therefore, consultation with 

FWS on the potential risk of lactofen to 

listed species will be necessary. 

Lactofen has not been evaluated under 

EDSP. Therefore, the Agency’s final 

registration review decision is 

dependent on the results of consultation 

under ESA section 7 with FWS and the 

evaluation of potential endocrine 

disrupter risk. Pending the outcome of 

these actions, EPA is issuing an interim 

registration review decision for lactofen. 

Macleaya Extract (Interim Decision). 

The registration review docket for 

macleaya extract (EPA–HQ–OPP–2011– 

0172) opened in March 2011. Macleaya 

extract is a plant extract of Macleaya 

cordata, and is registered for use only in 

enclosed commercial greenhouses, as an 

ornamental plant fungicide for the 

control of foliar fungal diseases. There 

are no registered food uses of macleaya 

extract. EPA completed a qualitative 

draft human health risk assessment for 

all macleaya extract uses. No risks of 

concern were identified. The Agency 

did not conduct a comprehensive 

ecological risk assessment since the use 

pattern does not likely result in outdoor 

exposures. However, the Agency 

completed a qualitative endangered 

species assessment for the greenhouse 

use. No risks of concern were identified 

and the Agency has made a ‘‘no effect’’ 

determination for federally listed 

species and designated critical habitat. 

Macleaya extract has not been evaluated 

under the EDSP. Therefore, the 

Agency’s final registration review 

decision is dependent upon the result of 

the evaluation of potential endocrine 

disruptor risk. The EPA is issuing an 

interim registration review decision for 

macleaya extract. 

Trinexapac-ethyl (Interim Decision) 

The registration review docket for 

trinexapac-ethyl (EPA–HQ–OPP–2008– 

0657) opened in a notice published in 

the Federal Register of September 15, 

2008 (73 FR 53244) (FRL–8381–3). 

Trinexapac-ethyl is a plant growth 

regulator registered for use by 

homeowners and professional 

applicators to manage growth of barley, 

grasses grown for seed, oats, sugarcane, 

triticale, turf grass, and wheat. Turf 

grass uses include athletic fields and 

parks, commercial and residential 

lawns, golf courses, and sod farms. It is 

also registered for application around 

flower beds, ornamental trees, and 

shrubs. EPA conducted a human health 

risk assessment and did not identify any 

risks of concern. In addition, EPA 

conducted an ecological risk 

assessment. Based on low risk estimates, 

and the conservative nature of the risk 

assessment, the Agency does not 

anticipate ecological risks of concern for 

assessed taxa from currently registered 

uses of trinexapac-ethyl. The Agency is 

not proposing mitigation changes at this 

time. However, the Agency is proposing 

that labels clarify the single-maximum 

application rate for liquid turf end-use 

products. Two comments were received 

for the trinexapac-ethyl proposed 

interim decision on the detail of the risk 

assessment. These comments did not 

change the interim decision. The risk 

assessment for trinexapac-ethyl did not 

come to a conclusion of ‘‘no effect’’ to 

listed species. Therefore, consultation 

with the Services on the potential risk 

of trinexapac-ethyl to listed species will 

be necessary. Trinexapac-ethyl has not 

been evaluated under EDSP. Therefore, 

the Agency’s final registration review 

decision is dependent on the result of 

consultation under ESA section 7 with 

FWS and the evaluation of potential 

endocrine disrupter risk. Pending the 

outcome of these actions, EPA is issuing 

an interim registration review decision 

for trinexapac-ethyl. 

Quizalofop (Interim Decision). The 

registration review docket for quizalofop 

(EPA–HQ–OPP–2007–1089) opened in 

2007. Quizalofop is a selective postemergence herbicide and appears as two 

different isomers: quizalofop-ethyl and 

quizalofop-p-ethyl. Quizalofop-ethyl is a 

50/50 racemic mixture of R- and Senantiomers and there are no active 

pesticide registrations of this isomer. 

Quizalofop-p-ethyl is the purified Renantiomer and the pesticidally active 

isomer. For the Agency’s purposes, both 

isomers will be referred to collectively 

as quizalofop. Quizalofop is registered 

to control annual and perennial grasses 

in various crops including Chinese 

cabbage, cotton, garlic, grains, legumes, 

mint, pineapple, soybean, sugar beets, 

and sunflower. Quizalofop is also used 

in non-agricultural settings, such as 

cottonwood and poplar plantations, 

fencerows, roadsides, and other 

uncultivated areas. EPA conducted a 

risk assessment for both human health 

and ecological risk. No risks of concern 

were identified in the human health risk 

assessment. The ecological risk 

assessment indicated potential risks to 

amphibians, freshwater fish, non-target 

monocots, and terrestrial mammals. The 

Agency will modify the application 

directions for quizalofop to reduce spray 

drift risk to non-target organisms. The 

screening-level endangered species 

assessment did not come to a 

conclusion of ‘‘no effect’’ to listed 

species, therefore, consultation with 

FWS on the potential risk of quizalofop 

to listed species will be necessary. 

Quizalofop has not been evaluated 

under EDSP. Therefore, the Agency’s 

final registration review decision is 

dependent on the result of consultation 

under ESA section 7 with FWS and the 

evaluation of potential endocrine 

disruptor risk. Pending the outcome of 

these actions, EPA is issuing an interim 

registration review decision for 

quizalofop. 

Pursuant to 40 CFR 155.58(c), the 

registration review case docket for 4- 

CPA (Case 2115), Allethrins (Case 0473), 

Clofentezine (Case 7602), Cyromazine 

(Case 7439), Fosthiazate (Case 7604), 

Hexythiazox (Case 7404), Lactofen (Case 

7210), Macleaya Extract (Case 7024), 

Trinexapac-ethyl (Case 7228), and 

Quizalofop (Case 7215) will remain 

open until all actions required in the 

final/interim decision have been 

completed. 

Background on the registration review 

program is provided at: http://www.epa.

gov/oppsrrd1/registration_review. Links 

to earlier documents related to the 

registration review of this pesticide are 

provided at: http://www2.epa.gov/

pesticide-reevaluation/individualpesticides-registration-review. 

Authority: 7 U.S.C. 136 et seq. 

Dated: December 16, 2014. 

Richard P. Keigwin, Jr., 

Director, Pesticide Re-Evaluation Division, 

Office of Pesticide Programs. 

[FR Doc. 2014–30214 Filed 12–23–14; 8:45 am] 

BILLING CODE 6560–50–P 

ENVIRONMENTAL PROTECTION 

AGENCY 

[EPA–HQ–OPP–2014–0814; FRL–9919–24] 

Registration Review Proposed Interim 

Decisions; Notice of Availability 

AGENCY: Environmental Protection 

Agency (EPA). 

ACTION: Notice. 

SUMMARY: This notice announces the 

availability of EPA’s proposed interim 

registration review decisions and opens 

a public comment. Registration review 

is EPA’s periodic review of pesticide 

registrations to ensure that each 

pesticide continues to satisfy the 

statutory standard for registration, that 

is, that the pesticide can perform its 

intended function without unreasonable 

adverse effects on human health or the 

environment. Through this program, 

EPA is ensuring that each pesticide’s 

registration is based on current 

scientific and other knowledge, 

mstockstill on DSK4VPTVN1PROD with NOTICES